Education
About Us
Working with TipRanks
Follow Us
Purple Biotech Ltd. (IL:PPBT)
:PPBT
PPBT Stock Chart & Stats
1.20
>-0.01(-5.19%)
At close: 4:00 PM EST
1.20
>-0.01(-5.19%)
Day’s Range― - ―
52-Week Range0.00 - 5.70
Previous CloseN/A
Volume1.16M
Average Volume (3M)8.90M
Market Cap
₪18.58M
Enterprise Value-7.59M
Total Cash (Recent Filing)₪10.45M
Total Debt (Recent Filing)₪256.00K
Price to Earnings (P/E)―
Beta0.26
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,858,479,500
10 Day Avg. Volume1,387,469
30 Day Avg. Volume8,902,795
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.32
Price to Sales (P/S)0.00
P/FCF Ratio-0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage provides durable financial flexibility for a clinical-stage biotech: it lowers insolvency risk and supports continued funding of trials or partnership deals without immediate refinancing pressure, allowing management to pursue development milestones.
Partnership-driven Revenue ModelA collaboration-focused model aligns risk and capital with larger partners, enabling Purple to fund clinical development and access commercial capabilities without building full-scale commercial infrastructure, preserving capital and strategic optionality over the medium term.
Narrowing Net LossReduced net losses signal progress in cost management or milestone-related inflows, extending runway and improving the odds of reaching value-inflection events. Sustained improvement enhances ability to fund programs or negotiate favorable partnerships without urgent dilution.
Bears Say
Pre-revenue ProfileBeing pre-revenue creates persistent execution and commercialization risk: the company depends on successful clinical outcomes or partner deals to generate revenue, leaving long-term cash generation uncertain and shareholder value contingent on binary development milestones.
Persistent Cash BurnSustained negative operating and free cash flow depletes reserves and forces reliance on financing or partner payments, which can be dilutive or conditional. Over months, continued cash burn constrains R&D pacing and narrows strategic options if funding events delay.
Negative Returns & Asset DeclineNegative ROE and declining equity/assets indicate ongoing value dilution from losses; if persistent, this erodes shareholder capital and weakens negotiating leverage with partners or financiers, increasing the likelihood of dilutive financings or unfavorable deal terms.
Purple Biotech News
PPBT FAQ
What was Purple Biotech Ltd.’s price range in the past 12 months?
Purple Biotech Ltd. lowest stock price was 0.00 and its highest was 5.70 in the past 12 months.
What is Purple Biotech Ltd.’s market cap?
Purple Biotech Ltd.’s market cap is ₪18.58M.
When is Purple Biotech Ltd.’s upcoming earnings report date?
Purple Biotech Ltd.’s upcoming earnings report date is May 27, 2026 which is in 83 days.
How were Purple Biotech Ltd.’s earnings last quarter?
Currently, no data Available
Is Purple Biotech Ltd. overvalued?
According to Wall Street analysts Purple Biotech Ltd.’s price is currently Overvalued.
Does Purple Biotech Ltd. pay dividends?
Purple Biotech Ltd. pays a Notavailable dividend of 249.549 which represents an annual dividend yield of N/A. See more information on Purple Biotech Ltd. dividends here
What is Purple Biotech Ltd.’s EPS estimate?
Purple Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Purple Biotech Ltd. have?
Purple Biotech Ltd. has 1,858,479,500 shares outstanding.
What happened to Purple Biotech Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Purple Biotech Ltd.?
Currently, no hedge funds are holding shares in IL:PPBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Purple Biotech Ltd.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.